The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Aquestive Therapeutics Inc shares valued at $473,701 were sold by Jung Cassie on Oct 15 ’25. At $7.01 per share, Jung Cassie sold 67,575 shares. The insider’s holdings dropped to 240,771 shares worth approximately $1.6 million following the completion of this transaction.
Also, Kraus Carl N sold 20,272 shares, netting a total of over 141,904 in proceeds. Following the sale of shares at $7.00 each, the insider now holds 282,475 shares.
Before that, Boyd Peter E. had sold 10,000 shares from its account. In a trade valued at $70,000, the insider traded Aquestive Therapeutics Inc shares for $7.00 each. Upon closing the transaction, the insider’s holdings decreased to 10,000 shares, worth approximately $1.79 million.
Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of May 10, 2024, Leerink Partners has initiated its “an Outperform” rating for AQST. Earlier on April 11, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for AQST stock.
Analyzing AQST Stock Performance
On last trading session, Aquestive Therapeutics Inc [NASDAQ: AQST] rose 2.78% to $6.66. The stock’s lowest price that day was $6.53, but it reached a high of $6.925 in the same session. During the last five days, there has been a drop of approximately -5.06%. Over the course of the year, Aquestive Therapeutics Inc shares have jumped approximately 21.31%. Shares of the company reached a 52-week high of $7.55 on 10/20/25 and a 52-week low of $2.12 on 05/13/25.
Support And Resistance Levels for Aquestive Therapeutics Inc (AQST)
According to the 24-hour chart, there is a support level at 6.49, which, if violated, would cause prices to drop to 6.31. In the upper region, resistance lies at 6.88. The next price resistance is at 7.10. RSI (Relative Strength Index) is 54.38 on the 14-day chart, showing neutral technical sentiment.
Is Aquestive Therapeutics Inc subject to short interest?
Stocks of Aquestive Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 3.37 million shares to 12.25 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 8.88 million shares. A jump of 27.53% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.11 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.11.
Which companies own the most shares of Aquestive Therapeutics Inc (AQST)?
In terms of Aquestive Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 85.19% from the previous closing price of $6.48. Analysts anticipate Aquestive Therapeutics Inc stock to reach 12 by 2025, with the lowest price target being 12. In spite of this, 3 analysts ranked Aquestive Therapeutics Inc stock as Buy at the end of 2025. On March 28, 2024, Raymond James assigned a price target of “an Outperform” to the stock and initiated coverage with a $7.
